Combination venetoclax and olverembatinib (HQP1351) as a successful therapeutic strategy for relapsed/refractory (R/R) mixed-phenotype blast phase of chronic myeloid leukemia.
Tongtong Zhang, Haixia Zhou, Mingzhu Xu, Chongsheng Qian, Aining Sun, Depei Wu, Shengli Xue
Author Information
- Tongtong Zhang: Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China. ORCID
- Haixia Zhou: Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
- Mingzhu Xu: Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
- Chongsheng Qian: Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
- Aining Sun: Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
- Depei Wu: Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
- Shengli Xue: Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China. slxue@suda.edu.cn.
No abstract text available.
- Melo JV, Barnes DJ (2007) Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 7(6):441–453
[DOI: 10.1038/nrc2147]
- Jiang Q, Li Z, Qin Y et al (2022) Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol 15(1):113
[DOI: 10.1186/s13045-022-01334-z]
- Dhillon S (2022) Olverembatinib: First Approval. Drugs 82(4):469–475
[DOI: 10.1007/s40265-022-01680-9]
- Liu X, Wang G, Yan X et al (2019) Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors. Cell Biosci 9:88
[DOI: 10.1186/s13578-019-0351-6]
- Valentin R, Grabow S, Davids MS (2018) The rise of apoptosis: targeting apoptosis in hematologic malignancies. Blood 132(12):1248–1264
[DOI: 10.1182/blood-2018-02-791350]
- Carter BZ, Mak PY, Mu H et al (2016) Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Sci Transl Med 8(355):355ra117
[DOI: 10.1126/scitranslmed.aag1180]
- Short NJ, Konopleva M, Kadia T et al (2021) An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol 96(7):E229–E232
[DOI: 10.1002/ajh.26175]
- Maiti A, Franquiz MJ, Ravandi F et al (2020) Venetoclax and BCR-ABL tyrosine kinase inhibitor combinations: outcome in patients with Philadelphia chromosome-positive advanced myeloid leukemias. Acta Haematol 143(6):567–573
[DOI: 10.1159/000506346]
- Fang DD, Zhu H, Tang Q et al (2021) FLT3 inhibition by olverem batinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia. Transl Oncol 15(1):101244
[DOI: 10.1016/j.tranon.2021.101244]
- Wang N, He J, Liu F (2022) Venetoclax in combination with hypomethylating agents for the treatment of treatment-naive B/myeloid mixed-phenotype acute leukemia and relapsed/refractory acute myeloid leukemia: a report of 3 cases. Chemotherapy 67(3):178–182
[DOI: 10.1159/000519882]
- 81970138/National Natural Science Foundation of China
- 81900130/National Natural Science Foundation of China
- 2020ZKMB05/Translational Research Grant of NCRCH
- BE2021649/Social Development Project of the Science and Technology Department of Jiangsu
- GSWS2019007/Gusu Key Medical Talent Program
Humans
Blast Crisis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Bridged Bicyclo Compounds, Heterocyclic
Antineoplastic Combined Chemotherapy Protocols
Leukemia, Myeloid, Acute
venetoclax
olverembatinib
Bridged Bicyclo Compounds, Heterocyclic
